CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Cell Genesys, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Cell Genesys, Inc.
500 Forbes Boulevard,
Phone: (650) 266-3000p:650 266-3000 South San Francisco, CA  94080  United States Ticker: CEGE CEGE

This company was Merged or Acquired on 10/14/2009.
Cell Genesys, Inc. was merged with and into Biosante Pharmaceuticals Inc., with Biosante Pharmaceuticals Inc. being the surviving corporation.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company

Business Summary
Cell Genesys, Inc. (Cell Genesys) is a biotechnology company focused on the development and commercialization of biological therapies for patients with cancer. The Company has developed cell-based cancer immunotherapies and oncolytic virus therapies to treat different types of cancer. Its clinical stage cancer programs involve cell- or viral-based products that have been modified to impart disease-fighting characteristics. In August 2008, Cell Genesys terminated enrollment and administration of GVAX immunotherapy for prostate cancer in VITAL-2, the second of the two Phase III clinical trials in advanced prostate cancer. In October 2009, BioSante Pharmaceuticals, Inc. and Cell Genesys, Inc. announced the completion of the merger of Cell Genesys, Inc. with and into BioSante Pharmaceuticals, Inc., with BioSante Pharmaceuticals, Inc. as the surviving company. Pursuant to the merger, BioSante Pharmaceuticals, Inc. has acquired all of the outstanding shares of Cell Genesys, Inc.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
6/30/200912/31/2008YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Senior Vice President - Regulatory Affairs and Portfolio Management Carol C.Grundfest 54 7/1/2003 7/1/2003

Business Names
Business Name
CEGE
Cell Genesys Limited

General Information
Number of Employees: 61 (As of 12/31/2008)
Outstanding Shares: 109,650,787 (As of 8/5/2009)
Shareholders: 17,175
Stock Exchange: NASD
Federal Tax Id: 943061375
Fax Number: (650) 266-3010
Email Address: ir@cellgenesys.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023